HAMILTON, Ontario, July 08, 2021 — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed three new contracts with home health agencies in Texas to provide its iUGO Care platform to their chronic disease patients.
“Home health agencies in Texas were hit particularly hard by the global pandemic, so it is extremely encouraging to see this segment of the market getting back to normal operations,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “All three of these new clients will go live this month. Onboarding with all clients is continuing to accelerate every week in keeping with the Company’s guidance for the second half of calendar year 2021. As hospitals begin to work through the backlog of procedures that were postponed over the last year and a half due to COVID-19, the pressure on community healthcare organizations such as physician practices and home health agencies to keep chronic disease patients out of hospital and in their own homes will continue to increase. This is expected to further fuel significant growth for the Company through 2021 and beyond.”
Reliq Health
Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.
ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director